KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBIT (2016 - 2025)

Historic EBIT for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$96.3 million.

  • Xenon Pharmaceuticals' EBIT fell 3075.63% to -$96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.8 million, marking a year-over-year decrease of 3336.93%. This contributed to the annual value of -$279.3 million for FY2024, which is 3048.02% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' EBIT is -$96.3 million, which was down 3075.63% from -$94.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year EBIT high stood at -$15.6 million for Q3 2021, and its period low was -$96.3 million during Q3 2025.
  • Its 5-year average for EBIT is -$50.8 million, with a median of -$53.7 million in 2023.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 338266.25% in 2021, then plummeted by 815.74% in 2022.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' EBIT stood at -$24.8 million in 2021, then crashed by 74.45% to -$43.3 million in 2022, then dropped by 23.92% to -$53.7 million in 2023, then plummeted by 44.29% to -$77.5 million in 2024, then dropped by 24.34% to -$96.3 million in 2025.
  • Its last three reported values are -$96.3 million in Q3 2025, -$94.2 million for Q2 2025, and -$72.7 million during Q1 2025.